A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL

Trial Profile

A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Inebilizumab (Primary) ; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Ifosfamide; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 04 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2016 This trial is discontinued in Czech Republic according to European Clinical Trials Database record.
    • 30 Jun 2016 This trial is discontinued in Germany ( End date: 17 Jun 2016) and suspended in Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top